-

Schrödinger to Host Platform Day on October 6, 2022

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that the company will host Platform Day in New York City on Thursday, October 6, 2022, beginning at 10:00 AM ET. Members of Schrödinger’s team will provide a detailed review of the company's physics-based, computational technology, provide case studies from its drug discovery collaborations and proprietary pipeline, and discuss the business opportunity ahead.

Schrödinger’s Platform Day will be a hybrid event, with limited in-person attendance available to members of the investment community, and a simultaneous webcast will be available for individual investors and other interested parties who wish to join virtually.

The live presentation can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately 90 days. To participate in the live webcast, please register for the event here. It is recommended that participants register at least 15 minutes in advance of the event.

About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 700 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Twitter, or visit our blog, Extrapolations.com.

Contacts

Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Tracy Lessor
Schrödinger, Inc.
tracy.lessor@schrodinger.com
617-519-9827

Industry:

Schrödinger, Inc.

NASDAQ:SDGR
Release Summary
Schrödinger announced that it will host Platform Day on October 6, 2022.
Release Versions
English
$Cashtags
$SDGR

Contacts

Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Tracy Lessor
Schrödinger, Inc.
tracy.lessor@schrodinger.com
617-519-9827

More News From Schrödinger, Inc.

Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its physics+AI computational platform and serving as a global leader in computational molecular discovery. “In 2025, we witnessed the continued impact of scaling ‘physics+AI’ to solve the challenges of data scarcity and to accelerate the discovery of differentiated molecules. We...

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows. “As a lead...

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on December 15, 2025, the company granted restricted stock units (RSUs) with respect to 2,666 shares of the company’s common stock to 6 newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement t...
Back to Newsroom